Newsadmin2024-09-11T02:11:22+00:00

News

2024

11 September 2024 Eye Co Wins Ethics Approval for Efficacy Study in dry AMD.
07 May 2024 Chairs Update at Eye Co.

2023

12 September 2023 Eye Co Granted Further Jurisdiction for its dry AMD Patent.
12 July 2023 Eye Co Granted Significant Patent in the United States of America.
15 June 2023 Chairman to retire after 3 terms as Director.

2022

03 November 2022 Results of Phase 1B Fludrocortisone Study Featured
02 November 2022 A Phase 1B Study of the Safety and Tolerability of
the Mineralocorticoid Fludrocortisone Acetate in Patients with Geographic Atrophy

10 JULY 2022 Eye Co’s Phase 1b Safety Study involving Fludrocortisone Acetate Published in BMJ.
9 March 2022 Eye Co Gains Ethics Approval

2021

December 2021 EXPERIMENTAL EYE RESEARCH 212
01 November 2021 EYE CO COMPLETES PHASE 1B SAFETY STUDY
26 September 2021 SUPERIOR EFFECTIVENESS OF FLUDROCORTISONE CONFIRMED IN PEER REVIEWED JOURNAL
25 September 2021 ANTI-INFLAMMATORY AND NEUROPROTECTIVE PROPERTIES OF THE CORTICOSTEROID FLUDROCORTISONE IN RETINAL DEGENERATION
12 August 2021 EYE CO IS GRANTED PATENT AUG 2021

2020

20 November 2020 EYE CO ANNOUNCEMENT RE SAFETY STUDY NOV 2020
16 September 2020 EYE CO APPOINTS EXPERIENCED DIRECTOR TO ITS FIDUCIARY BOARD.
27 August 2020 UPDATE ON FLUDROCORTISONE STUDY IN HUMANS WITH DRY…
09 April 2020 UPDATE ON FLUDROCORTISONE STUDY IN HUMANS WITH DRY…
22 January 2020 EYE CO SHAREHOLDER UPDATE JAN 2020

2019

05 November 2019 EYE CO ANNOUNCEMENT SAFETY STUDY PROGRESS
18 September 2019 EYE CO ANNOUNCES FURTHER STUDIES AT ANU
12 June 2019 EYE CO’S SCIENTIFIC ADVISORY BOARD JUNE 2019
22 January 2019 EYE CO ANNOUNCES STRATEGIC ALLIANCE WITH ANU.
26 April 2019 EYE CO ANNOUNCES PATENT FILING APRIL 2019.
20 March 2019 EYE CO ANNOUNCES PATENT FILING MARCH 2019.
27 May 2019 EYE CO’S SCIENTIFIC ADVISORY BOARD MAY 2019

2018

16 November 2018 EYE CO’S FLUDROCORTISONE TO COMMENCE FIRST TRIALSN.